Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.
Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD ...
The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...
COPD (Chronic Obstructive Pulmonary Disease) is a lung disease that causes breathing difficulties, chronic cough, and mucus.
Changes in people’s voices recoded on a smartphone can signal a serious flare up in symptoms of chronic obstructive pulmonary ...
The approval makes COPD the sixth indication for the blockbuster treatment and makes Dupixent the first available biologic for the condition. As per a 27 September press announcement, Dupixent ...
Chronic obstructive lung disease, also known as chronic obstructive pulmonary disease (COPD), is a general term for a group ...
The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...
The 26,905 people who indicated experiencing these symptoms completed questionnaires ... and the other half to lung specialists and asthma/COPD educators (specially trained nurses or respiratory ...